Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2010

View Archived Issues

NeuroSearch claims new K(Ca)2.3 potassium channel activators

Effects of dalcetrapib and pravastatin on lipoprotein profile determined in dyslipidemia

U.K. scientists disclose novel antiviral neuraminidase inhibitors

Swiss researchers claim new guanidinium-modified porphyrins and phthalocyanines

Novel antibacterial agents discovered at University of Barcelona

Novartis claims new PI3K inhibitors for cancer therapy

CGRP receptor PET tracer [11C]-MK-4232 explores efficacy of antagonists in migraine

AC-1202 improves cognition in Alzheimer's disease

Beta-adrenoceptor blocker landiolol studied in early phase of acute myocardial infarction

Orally available selective CDK inhibitor AT-9311 discovered

Preclinical and clinical data support reovirus-based prostate cancer therapy ReoT3D

Cubist Pharmaceuticals plans to stop investing in the development of ecallantide

Genta begins confirmatory phase IIb trial of tesetaxel in gastric cancer

Safety board recommends continuation of Celsion's phase I/II ThermoDox trial in breast cancer

Allon Therapeutics reports imaging data on davenutide in schizophrenia

Nymox outlines new plans for phase III BPH drug NX-1207

FDA's metabolic division deems Repros' phase II Androxal trial protocol adequate

Daiichi Sankyo seeks approval in Japan for oral factor Xa inhibitor edoxaban

U.K.'s National Health Service recommends approval of Lilly's Alimta for advanced nonsquamous NSCLC

FDA conducts safety review of Orion's Stalevo for Parkinson's disease

Sanofi-aventis reports settlement on U.S. patent litigation for Eloxatin

Takeda and Janssen to comarket Alzheimer's disease therapeutic galantamine in Japan

Teijin and Astellas to market TMX-67 for hyperuricemia in gout patients in China and Hong Kong

Warner Chilcott assumes full commercial responsibility for Actonel in U.S.

Asahi Kasei grants Altheos exclusive rights to AK-138 series compounds for glaucoma

FDA grants Keryx's KRX-0401 fast track designation for refractory advanced colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...